• Aria CV, Inc. Raises $6.3M Series A

    December 19, 2014

    December 19, 2014 Aria CV, Inc., Saint Paul, MN—a developer of medical devices to treat heart failure related to pulmonary hypertension, today announced the initial closing of a $6.3 million Series A preferred equity financing. The financing round was led by Catalyst Health Ventures and includes Broadview Ventures and Cedar Point Capital.  The proceeds from this financing will be used to advance development and perform clinical testing of the device. Press Release

    Read More
  • Acesion Pharma Raises 15.2M DKK

    December 17, 2014

    December 17, 2014 Acesion Pharma raises 15.2 million DKK in new equity from Novo A/S and Broadview Ventures. Acesion Pharma, a Danish biotech company developing novel therapeutic treatment for atrial fibrillatin (AF), today announced that it has raised 15.2 million DKK (2.5 million USD) in a new equity investment round. The round included Boston-based Broadview Ventures as a new investor and current investor Novo Seeds. Press Release

    Read More
  • BioKier Takes a Shot at a New Kind of Diabetes Drug

    August 25, 2014

    August 25, 2014 BioKier Takes a Shot at a New Kind of Diabetes Drug: Chapel Hill, NC, drug developer BioKier is beginning human tests of a drug that, if successful, could replace these injection therapies with a pill that coaxes the body to regulate blood sugar levels on its own, says George Szewczyk, BioKier founder and CEO. If it works, BioKier’s approach could offer some advantages over blockbuster diabetes drugs currently available from big pharmaceutical companies.   Press Release

    Read More
  • miRagen Therapeutics Extends Research Collaboration with Servier

    June 23, 2014

    June 23, 2014 Servier and miRagen: Servier, an independent French research-based pharmaceutical company with a significant presence in Europe and emerging markets, and miRagen Therapeutics, Inc. a biopharmaceutical company developing innovative microRNA-based therapeutics, announced today that they have extended their research collaboration by two years to October 2016 to discover, develop, and commercialize drugs targeting microRNAs for cardiovascular disease. miRagen and Servier Research will continue preclinical research and development on multiple cardiovascular programs targeting microRNA

    Read More
  • CardiAQ Valve Technologies reports successful FIH implantation

    May 20, 2014

    May 20, 2014 CardiAQ™ Valve Technologies reports Successful First-in-Human Trans-Apical implantation of its Second Generation Transcatheter Mitral Valve. For the 50% of patients suffering from severe, symptomatic Mitral Regurgitation who are denied surgery due to procedural risk, Transcatheter Mitral Valve Implantationmay offer new hope for treatment. With its latest advancement, CardiAQ is now the only company in the TMVI space to have demonstrated procedural success with both Trans-Femoral and Trans-Apical Delivery Systems. Press Release

    Read More
  • ZZ Biotech announces Phase 2 Trial

    April 22, 2014

    April 22, 2014: ZZ Biotech announces Phase 2 Trial with 3K3A-APC in Stroke; Funds will be provided by NIH and Broadview Ventures ZZ Biotech today announced that the National Institutes of Health will support a multicenter Phase 2 clinical trial of its experimental drug, 3K3A-APC, in patients suffering from acute ischemic stroke.   Press Release

    Read More
  • InfoBionic Raises $17M Series B

    April 8, 2014

    April 8, 2014: InfoBionic™, an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management, today announced that it has closed the first tranche of a $17 million Series B financing, which was led by Safeguard Scientifics, Inc. (NYSE: SFE). Proceeds from the financing will enable InfoBionic to commercialize its MoMe™ System, a remote patient monitoring platform for cardiac arrhythmia detection, in Europe and the United States.   Press Release

    Read More
  • BioKier, Inc. Signs Exclusive License with UCL Business PLC

    March 14, 2014

    March 14, 2014:  BioKier, Inc. signs exclusive global license with UCL Business PLC for colonic delivery of gut hormone secretagogues for treatment of metabolic diseases including diabetes. BioKier, Inc. has entered into an exclusive license agreement with UCL Business PLC (UCLB) for the proprietary colon delivery technology (PhloralTM) developed by researchers at the UCL School of Pharmacy.   Press Release

    Read More
  • Remedy Pharmaceuticals Receives Financing from Broadview

    February 10, 2014

    February 10, 2014:  Broadview Ventures invests in novel stroke drug company Remedy Pharmaceuticals. Remedy Pharmaceuticals, Inc. today announced that it completed an equity financing from a new investor, Broadview Ventures, for an undisclosed amount. Funds will be used to accelerate Remedy’s GAMES-RP clinical trial of its central nervous system drug RP-1127.   Press Release

    Read More
  • InfoBionic receives CE Mark for MoMe™ System

    January 8, 2014

    January 8, 2014:  InfoBionic™, an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management, today announced receipt of CE Mark for the MoMe™ System for cardiac arrhythmia monitoring. The MoMe System is the first universal remote patient monitoring platform with seamless transition between Holter, Event, and Mobile Cardiac Telemetry (MCT) modes.   Press Release

    Read More